Urine Neural Thread Protein Measurements in Alzheimer Disease

Young Chul Youn, Kun Woo Park, Seol Heui Han, Sang Yun Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study. Design: A prospective blinded multicentered study. Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson's disease (PD) (n = 20), and healthy controls (n = 22) were enrolled consecutively in 4 neurology centers. Measurements: A first morning urine sample was obtained from each subject. Urine NTP measurement using competitive ELISA was tested at the central laboratory and compared with AD and PD patients and healthy controls (HC). The testing laboratory was blinded to clinical information. Results: The mean assay value in AD (n = 49, 26.8 ± 9.4 μg/mL) was significantly higher than in HC (n = 22, 18.1 ± 6.7 μg/mL) (P ≤ .001) and than in PD (n = 20, 21.0 ± 8.5 μg/mL) (P ≤ .05). Levels of 21.6 μg/mL or higher were found in 81.6% of all AD cases, in 30.0% of PD cases, and in 13.6% of HC. Urine NTP assay measurements of AD with a Clinical Dementia Rate (CDR) of 0.5 (n = 10, 24.2 ± 5.9 μg/mL, P = .063) or of 1.0 (n = 24, 30.1 ± 10.9 μg/mL, P = .000) were significantly higher than in HC. However, the AD patients with CDR of 2.0 (n = 9, 23.1 ± 7.3 μg/mL, P = .136) were not significant. Conclusion: Urine NTP could be used as a safe and promising biochemical marker of early AD.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalJournal of the American Medical Directors Association
Volume12
Issue number5
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Alzheimer Disease
Urine
Proteins
Parkinson Disease
Dementia
Phosphoproteins
Neurology
Membrane Proteins
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • Alzheimer disease
  • Biological marker
  • Neural thread protein
  • Parkinson disease

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health Policy

Cite this

Urine Neural Thread Protein Measurements in Alzheimer Disease. / Youn, Young Chul; Park, Kun Woo; Han, Seol Heui; Kim, Sang Yun.

In: Journal of the American Medical Directors Association, Vol. 12, No. 5, 01.06.2011, p. 372-376.

Research output: Contribution to journalArticle

Youn, Young Chul ; Park, Kun Woo ; Han, Seol Heui ; Kim, Sang Yun. / Urine Neural Thread Protein Measurements in Alzheimer Disease. In: Journal of the American Medical Directors Association. 2011 ; Vol. 12, No. 5. pp. 372-376.
@article{54a65f5d0b29450daee87869909ed40c,
title = "Urine Neural Thread Protein Measurements in Alzheimer Disease",
abstract = "Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study. Design: A prospective blinded multicentered study. Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson's disease (PD) (n = 20), and healthy controls (n = 22) were enrolled consecutively in 4 neurology centers. Measurements: A first morning urine sample was obtained from each subject. Urine NTP measurement using competitive ELISA was tested at the central laboratory and compared with AD and PD patients and healthy controls (HC). The testing laboratory was blinded to clinical information. Results: The mean assay value in AD (n = 49, 26.8 ± 9.4 μg/mL) was significantly higher than in HC (n = 22, 18.1 ± 6.7 μg/mL) (P ≤ .001) and than in PD (n = 20, 21.0 ± 8.5 μg/mL) (P ≤ .05). Levels of 21.6 μg/mL or higher were found in 81.6{\%} of all AD cases, in 30.0{\%} of PD cases, and in 13.6{\%} of HC. Urine NTP assay measurements of AD with a Clinical Dementia Rate (CDR) of 0.5 (n = 10, 24.2 ± 5.9 μg/mL, P = .063) or of 1.0 (n = 24, 30.1 ± 10.9 μg/mL, P = .000) were significantly higher than in HC. However, the AD patients with CDR of 2.0 (n = 9, 23.1 ± 7.3 μg/mL, P = .136) were not significant. Conclusion: Urine NTP could be used as a safe and promising biochemical marker of early AD.",
keywords = "Alzheimer disease, Biological marker, Neural thread protein, Parkinson disease",
author = "Youn, {Young Chul} and Park, {Kun Woo} and Han, {Seol Heui} and Kim, {Sang Yun}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.jamda.2010.03.004",
language = "English",
volume = "12",
pages = "372--376",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Urine Neural Thread Protein Measurements in Alzheimer Disease

AU - Youn, Young Chul

AU - Park, Kun Woo

AU - Han, Seol Heui

AU - Kim, Sang Yun

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study. Design: A prospective blinded multicentered study. Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson's disease (PD) (n = 20), and healthy controls (n = 22) were enrolled consecutively in 4 neurology centers. Measurements: A first morning urine sample was obtained from each subject. Urine NTP measurement using competitive ELISA was tested at the central laboratory and compared with AD and PD patients and healthy controls (HC). The testing laboratory was blinded to clinical information. Results: The mean assay value in AD (n = 49, 26.8 ± 9.4 μg/mL) was significantly higher than in HC (n = 22, 18.1 ± 6.7 μg/mL) (P ≤ .001) and than in PD (n = 20, 21.0 ± 8.5 μg/mL) (P ≤ .05). Levels of 21.6 μg/mL or higher were found in 81.6% of all AD cases, in 30.0% of PD cases, and in 13.6% of HC. Urine NTP assay measurements of AD with a Clinical Dementia Rate (CDR) of 0.5 (n = 10, 24.2 ± 5.9 μg/mL, P = .063) or of 1.0 (n = 24, 30.1 ± 10.9 μg/mL, P = .000) were significantly higher than in HC. However, the AD patients with CDR of 2.0 (n = 9, 23.1 ± 7.3 μg/mL, P = .136) were not significant. Conclusion: Urine NTP could be used as a safe and promising biochemical marker of early AD.

AB - Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study. Design: A prospective blinded multicentered study. Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson's disease (PD) (n = 20), and healthy controls (n = 22) were enrolled consecutively in 4 neurology centers. Measurements: A first morning urine sample was obtained from each subject. Urine NTP measurement using competitive ELISA was tested at the central laboratory and compared with AD and PD patients and healthy controls (HC). The testing laboratory was blinded to clinical information. Results: The mean assay value in AD (n = 49, 26.8 ± 9.4 μg/mL) was significantly higher than in HC (n = 22, 18.1 ± 6.7 μg/mL) (P ≤ .001) and than in PD (n = 20, 21.0 ± 8.5 μg/mL) (P ≤ .05). Levels of 21.6 μg/mL or higher were found in 81.6% of all AD cases, in 30.0% of PD cases, and in 13.6% of HC. Urine NTP assay measurements of AD with a Clinical Dementia Rate (CDR) of 0.5 (n = 10, 24.2 ± 5.9 μg/mL, P = .063) or of 1.0 (n = 24, 30.1 ± 10.9 μg/mL, P = .000) were significantly higher than in HC. However, the AD patients with CDR of 2.0 (n = 9, 23.1 ± 7.3 μg/mL, P = .136) were not significant. Conclusion: Urine NTP could be used as a safe and promising biochemical marker of early AD.

KW - Alzheimer disease

KW - Biological marker

KW - Neural thread protein

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=79956276498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956276498&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2010.03.004

DO - 10.1016/j.jamda.2010.03.004

M3 - Article

VL - 12

SP - 372

EP - 376

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 5

ER -